Neuren Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Neuren Pharmaceuticals has been growing earnings at an average annual rate of 52.9%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 50.5% per year. Neuren Pharmaceuticals's return on equity is 9%, and it has net margins of 47.1%.
Key information
52.95%
Earnings growth rate
53.05%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.22% |
| Revenue growth rate | 50.53% |
| Return on equity | 8.99% |
| Net Margin | 47.08% |
| Last Earnings Update | 31 Dec 2025 |
Recent past performance updates
Recent updates
NEU: Share Buyback Plan Will Support Bullish Long Term Outlook
Analysts have trimmed their 12 month price target for Neuren Pharmaceuticals from A$24.51 to A$23.45 as they factor in updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples. What's in the News Neuren Pharmaceuticals Limited (ASX:NEU) has announced a share repurchase program covering up to 6,350,631 shares, equal to 5% of its issued share capital, with all repurchased shares to be cancelled (company announcement).Slammed 30% Neuren Pharmaceuticals Limited (ASX:NEU) Screens Well Here But There Might Be A Catch
The Neuren Pharmaceuticals Limited ( ASX:NEU ) share price has fared very poorly over the last month, falling by a...Investors Shouldn't Be Too Comfortable With Neuren Pharmaceuticals' (ASX:NEU) Earnings
Unsurprisingly, Neuren Pharmaceuticals Limited's ( ASX:NEU ) stock price was strong on the back of its healthy earnings...Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 26% But Investors Aren't Buying For Growth
Despite an already strong run, Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have been powering on, with a gain of...Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders would be excited to see that the share price has had a great...
DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks
Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings.Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel
With a price-to-earnings (or "P/E") ratio of 10.1x Neuren Pharmaceuticals Limited ( ASX:NEU ) may be sending bullish...A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Key Insights The projected fair value for Neuren Pharmaceuticals is AU$13.55 based on 2 Stage Free Cash Flow to Equity...Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up
Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have had a really impressive month, gaining 26% after a shaky period...Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$15.24 based on 2 Stage Free Cash Flow to Equity Neuren...Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
The half-year results for Neuren Pharmaceuticals Limited ( ASX:NEU ) were released last week, making it a good time to...Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now
Neuren Pharmaceuticals Limited's ( ASX:NEU ) price-to-sales (or "P/S") ratio of 8.6x might make it look like a strong...Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely
You may think that with a price-to-sales (or "P/S") ratio of 10.8x Neuren Pharmaceuticals Limited ( ASX:NEU ) is a...An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$35.92 based on 2 Stage Free Cash Flow to Equity Current...Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors
Despite an already strong run, Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have been powering on, with a gain of...Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)
Key Insights Neuren Pharmaceuticals' estimated fair value is AU$15.62 based on 2 Stage Free Cash Flow to Equity With...This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year
Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Neuren...Revenue & Expenses Breakdown
How Neuren Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 25 | 65 | 30 | 6 | 0 |
| 30 Sep 25 | 142 | 90 | 6 | 0 |
| 30 Jun 25 | 219 | 149 | 5 | 0 |
| 31 Mar 25 | 218 | 146 | 5 | 0 |
| 31 Dec 24 | 217 | 142 | 5 | 0 |
| 30 Sep 24 | 206 | 130 | 5 | 0 |
| 30 Jun 24 | 195 | 117 | 5 | 0 |
| 31 Mar 24 | 214 | 137 | 6 | 0 |
| 31 Dec 23 | 232 | 157 | 6 | 0 |
| 30 Sep 23 | 155 | 106 | 5 | 0 |
| 30 Jun 23 | 78 | 55 | 4 | 0 |
| 31 Mar 23 | 47 | 28 | 4 | 0 |
| 31 Dec 22 | 15 | 0 | 3 | 0 |
| 30 Sep 22 | 9 | -3 | 3 | 0 |
| 30 Jun 22 | 3 | -7 | 3 | 0 |
| 31 Mar 22 | 3 | -7 | 3 | 0 |
| 31 Dec 21 | 3 | -8 | 2 | 0 |
| 30 Sep 21 | 2 | -10 | 2 | 0 |
| 30 Jun 21 | 1 | -12 | 2 | 0 |
| 31 Mar 21 | 1 | -11 | 2 | 0 |
| 31 Dec 20 | 1 | -9 | 2 | 0 |
| 30 Sep 20 | 1 | -8 | 2 | 0 |
| 30 Jun 20 | 0 | -8 | 2 | 0 |
| 31 Mar 20 | 0 | -9 | 2 | 0 |
| 31 Dec 19 | 0 | -11 | 2 | 0 |
| 30 Sep 19 | 7 | -6 | 2 | 0 |
| 30 Jun 19 | 14 | -1 | 2 | 0 |
| 31 Mar 19 | 14 | 1 | 2 | 0 |
| 31 Dec 18 | 14 | 3 | 2 | 0 |
| 30 Sep 18 | 7 | 3 | 2 | 0 |
| 30 Jun 18 | 1 | 3 | 1 | 0 |
| 31 Mar 18 | 1 | 3 | 2 | 0 |
| 31 Dec 17 | 1 | 3 | 2 | 0 |
| 30 Sep 17 | 2 | -2 | 2 | 0 |
| 30 Jun 17 | 3 | -8 | 2 | 0 |
| 31 Mar 17 | 3 | -10 | 2 | 0 |
| 31 Dec 16 | 3 | -12 | 2 | 0 |
| 30 Sep 16 | 2 | -14 | 2 | 0 |
| 30 Jun 16 | 0 | -15 | 3 | 0 |
| 31 Mar 16 | 1 | -14 | 3 | 0 |
| 31 Dec 15 | 2 | -13 | 3 | 0 |
| 30 Sep 15 | 2 | -11 | 3 | 0 |
| 30 Jun 15 | 3 | -9 | 3 | 0 |
Quality Earnings: NEU has high quality earnings.
Growing Profit Margin: NEU's current net profit margins (47.1%) are lower than last year (65.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NEU has become profitable over the past 5 years, growing earnings by 52.9% per year.
Accelerating Growth: NEU's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NEU had negative earnings growth (-78.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-17.4%).
Return on Equity
High ROE: NEU's Return on Equity (9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/02 07:41 |
| End of Day Share Price | 2026/06/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuren Pharmaceuticals Limited is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Melissa Benson | Barrenjoey Markets Pty Limited |
| Thomas Wakim | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |